Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer

被引:159
作者
Osada, H [1 ]
Takahashi, T [1 ]
机构
[1] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan
关键词
tumor suppressor; oncogene; lung cancer;
D O I
10.1038/sj.onc.1205802
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer has become the leading cause of cancer death in many economically well-developed countries. Recent molecular biological studies have revealed that overt lung cancers frequently develop through sequential morphological steps, with the accumulation of multiple genetic and epigenetic alterations affecting both tumor suppressor genes and dominant oncogenes. Cell cycle progression needs to be properly regulated, while cells have built-in complex and minute mechanisms such as cell cycle checkpoints to maintain genomic integrity. Genes in the p16INK4A-RB and p14ARF-p53 pathways appear to be a major target for genetic alterations involved in the pathogenesis of lung cancer. Several oncogenes are also known to be altered in lung cancer, leading to the stimulation of autocrine/paracrine loops and activation of multiple signaling pathways. It is widely acknowledged that carcinogens in cigarette smoke are deeply involved in these multiple genetic alterations, mainly through the formation of DNA adducts. A current understanding of the molecular mechanisms of lung cancer pathogenesis and progression is presented in relation to cigarette smoking, an absolute major risk factor for lung cancer development, by reviewing genetic alterations of various tumor suppressor genes and oncogenes thus far identified in lung cancer, with brief summaries of their functions and regulation.
引用
收藏
页码:7421 / 7434
页数:14
相关论文
共 182 条
[41]   Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies [J].
Harris, CC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1442-1455
[42]  
Haruki N, 2000, CANCER RES, V60, P4689
[43]   Persistent increase in chromosome instability in lung cancer - Possible indirect involvement of p53 inactivation [J].
Haruki, N ;
Harano, T ;
Masuda, A ;
Kiyono, T ;
Takahashi, T ;
Tatematsu, Y ;
Shimizu, S ;
Mitsudomi, T ;
Konishi, H ;
Osada, H ;
Fujii, Y ;
Takahashi, T .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (04) :1345-1352
[44]  
Hatanaka H, 2001, CLIN CANCER RES, V7, P1287
[45]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[46]  
HENSEL CH, 1990, CANCER RES, V50, P3067
[47]   14-3-3σ is a p53-regulated inhibitor of G2/M progression [J].
Hermeking, H ;
Lengauer, C ;
Polyak, K ;
He, TC ;
Zhang, L ;
Thiagalingam, S ;
Kinzler, KW ;
Vogelstein, B .
MOLECULAR CELL, 1997, 1 (01) :3-11
[48]  
HIBI K, 1992, ONCOGENE, V7, P445
[49]   MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation [J].
Higashiyama, M ;
Doi, O ;
Kodama, K ;
Yokouchi, H ;
Kasugai, T ;
Ishiguro, S ;
Takami, K ;
Nakayama, T ;
Nishisho, I .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1302-1308
[50]   TELOMERASE ACTIVITY IN SMALL-CELL AND NON-SMALL-CELL LUNG CANCERS [J].
HIYAMA, K ;
HIYAMA, E ;
ISHIOKA, S ;
YAMAKIDO, M ;
INAI, K ;
GAZDAR, AF ;
PIATYSZEK, MA ;
SHAY, JW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (12) :895-902